Özüm Atasoy1, Oytun Erbaş2

1Department of Radiation Oncology, Kartal Dr. Lütfi Kırdar Training and Research Hospital, Istanbul, Turkey
2Department of Physiology, Istanbul Bilim University Faculty of Medicine, Istanbul, Turkey

Keywords: Androgen deprivation therapy, chemotherapy, prostate cancer, radiotherapy


Prostate cancer is the most common cancer among men and is the second most common cause of cancer-related death in men following lung cancer. It is generally slow growing. The main risk factor is elderly age. Prognosis is generally good, but may vary depending on its pathologic subtype. Adenocarcinoma, which accounts for over 95% of cases, responds especially well when treated as localized disease. The main methods of treatment include radical prostatectomy, radiotherapy, and active surveillance, as well as chemotherapy, androgen deprivation treatment, and Radium-223.

Cite this article as: Atasoy Ö, Erbaş O. Up to date of prostate cancer. D J Med Sci 2020;6(2):92-102.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Financial Disclosure

The authors received no financial support for the research and/or authorship of this article.